Sulfasalazine for Anti-Canine Melanoma

Advantages

  •  New drug candidate for canine melanoma based on molecular mechanism.
  • Sulfasalazine has been used for human RA therapy against different target with different formulation to this technology.
  • There is no treatment methods for canine melanoma.

Background and Technology

Canine melanoma is highly malignant, invasive and metastatic, and there is no effective treatment method because of resistance to chemotherapy and radiotherapy.
Here, we found overexpression of xCT (cystine/glutamate transporter) in canine melanoma involved in scavenging of ROS which cause the resistance. We further demonstrated that an xCT inhibitor, sulfasalazine, improved the chemotherapy and radiotherapy-resistance.
Sulfasalazine was first synthesized by combining sulfapyridine, an antibiotic, with 5-aminosalicylic acid, an anti-inflammatory agent, linked by an azo bridge in 1950s. It is commonly used to treat human chronic inflammatory diseases and rheumatoid arthritis.

 

Data


Reference:  Nagane M and Kanai E et al, Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma, PLOS One, 2018

Patent

Pending, unpublished.

Researcher

Dr. Masaaki Nagane (School of Veterinary Medicine, Azabu University)

Expectations

We are looking for a veterinary pharmaceutical company who will further develop and commercialize this technology with us based on a technology licensing or collaboration research.

Product No:BK-02865

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.